PT  - JOURNAL ARTICLE
AU  - Damir Bojadzic
AU  - Oscar Alcazar
AU  - Peter Buchwald
TI  - Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike – ACE2 Protein-Protein Interaction – A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19
AID  - 10.1101/2020.08.29.273441
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.08.29.273441
4099  - http://biorxiv.org/content/early/2020/08/31/2020.08.29.273441.short
4100  - http://biorxiv.org/content/early/2020/08/31/2020.08.29.273441.full
AB  - Due to our interest in the chemical space of organic dyes to identify potential small-molecule inhibitors (SMIs) for protein-protein interactions (PPIs), we initiated a screen of such compounds to assess their inhibitory activity against the interaction between SARS-CoV-2 spike protein and its cognate receptor ACE2, which is the first critical step initiating the viral attachment and entry of this coronavirus responsible for the ongoing COVID-19 pandemic. As part of this, we found that methylene blue, a tricyclic phenothiazine compound approved by the FDA for the treatment of methemoglobinemia and used for other medical applications (including the inactivation of viruses in blood products prior to transfusion when activated by light), inhibits this interaction. We confirmed that it does so in a concentration-dependent manner with a low micromolar half-maximal inhibitory concentration (IC50 = 3 μM) in our protein-based ELISA-type setup, while chloroquine, siramesine, and suramin showed no inhibitory activity in this assay. Erythrosine B, which we have shown before to be a promiscuous SMI of PPIs, also inhibited this interaction with an activity similar, possibly slightly higher, than those found for it for other PPIs. This PPI inhibitory activity of methylene blue could contribute to its antiviral activity against SARS-CoV-2 even in the absence of light by blocking its attachment to ACE2-expressing cells and making this inexpensive and widely available drug potentially useful in the prevention and treatment of COVID-19 as an oral or inhaled medication.Competing Interest StatementThe authors have declared no competing interest.ACE2angiotensin converting enzyme 2;CoVcoronavirus;MeBlumethylene blue;PPIprotein-protein interaction;SARSsevere acute respiratory syndrome;SMIsmall-molecule inhibitor.